


REMARKS

After entry of this amendment claims 55-82 are pending. Support for the new claims is found throughout the disclosure with exemplary support as follows.

5	<u>Claim</u>	<u>Specification support</u>
	83-86	page 218, line 1, page 258, lines 5-13 and page 265, line 27 through page 266, line 2
	88-99 and	page 55, line 21 through page 105, line 25, page 111, line 9
10	102-112	through page 112, line 12, page 280, lines 1-9 and page 313, lines 1-10
	87, 101	page 111, line 9 through page 112, line 12
15	100	page 229, lines 20-23

RESTRICTION REQUIREMENT

In their response of January 28, 2003, Applicants elected the method of claim 70 (now new claim 98), i.e., treatment of hypercholesterolemia using the compound



Claims 83-87, 93-98, 100-101 and 107-111 read on this species. Applicants maintain their election of this subject matter in response to the restriction requirement.


CONCLUSION

An examination on the merits is respectfully requested. Applicants' representative can be reached at the number given below if the Office has any questions or would like to address any other matters that may arise.

5

Respectfully submitted,

10 Dated: 06-02-03



Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, CA 92121
Phone: 858-320-2569
Fax: 858-558-6470

15